An interesting press release from Feb this year!
Soliris® (eculizumab), the company's first product, is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH)1, a progressive and life-threatening disease characterized by the excessive destruction of red blood cells (hemolysis).2,3 Soliris is the only treatment for PNH that reduces hemolysis.1PNH is rare enough for Alexion to charge $400,000 a patient.
Now indication number two should have pivotal data by the end of the year. This would bring in another group of patients, who will pay at least $400,000 a year to get the drug for atypical hemolytic uremic syndrome (aHUS); they need more drug, about 50% more drug, than PNH patients. Every patient in Phase III for PNH benefited and the p-value was incredibly statistically significant. Alexion will add on country after country over the course of this year, ending with an important Japanese approval, and so it's a revenue/EPS powerhouse story.